Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
The REVISE-Diabesity trial investigates the efficacy of the Endobarrier device in conjunction with Liraglutide for treating obesity and type 2 diabetes in patients unresponsive to conventional therapies. Given the rising prevalence of obesity and T2DM, this study addresses a significant unmet medical need, potentially positioning the Endobarrier as a viable non-surgical alternative to bariatric surgery. The outcomes could enhance market competitiveness against existing GLP-1 receptor agonists and other obesity treatments, while also informing future product development strategies. Stakeholders should consider the implications of successful results on market access, reimbursement strategies, and potential partnerships for commercialization.
Indication: Type 2 Diabetes
Modality: small molecule
Target: GLP-1 receptor agonism and intestinal barrier modulation via Endobarrier device.
Sponsor: Sandwell & West Birmingham Hospitals NHS Trust
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GLP-1 receptor agonism and intestinal barrier modulation via Endobarrier device.
View original source fields
Condition raw: Type 2 Diabetes, Obesity, Diabesity
Condition normalized: Type 2 Diabetes, Obesity, Diabesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GLP-1 receptor agonism and intestinal barrier modulation via Endobarrier device.
Target normalized: GLP-1 receptor agonism and intestinal barrier modulation via Endobarrier device.